Wall Street Upgrades Two Biotech Stocks: STRO Price Target Tripled, ORIC Now a Buy
Wedbush lifts Sutro to $60 on STRO-004 hopes; ORIC upgraded on strong cancer data and big market potential.
/ 4 items
#ORIC↓
ORIC Shares Slide on Higher-Dose Side Effects — But 400mg Rinzimetostat Looks Best-in-Class
ORIC shares plunged after Phase 1b data showed higher side effects at 600mg rinzimetostat.
EZH2 Class Hit: ORIC Down After Tazverik Withdrawal
Oric Pharmaceuticals shares fell after Ipsen pulled Tazverik from all markets due to safety concerns in a key trial. Tazverik sales were already weak—a blow to confidence in similar EZH2 drugs like ORIC’s, even if they are not the same.
Major Biotech Upgrades and Coverage Initiations: Regeneron, Erasca, Protara, Design Therapeutics, Oric
Bank of America and Piper Sandler make bullish moves on top biotech stocks, including Regeneron, Erasca, Protara, Design Therapeutics, and Oric, highlighting growth potential, new drug updates, and pipeline opportunities.